Pernix Therapeutics (PTX) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pernix Therapeutics (PTX) PT Trimmed to $14 at Brean Capital Amid Weak Q2
August 7, 2015 8:57 AM EDTBrean Capital analyst Difei Yang lowered the price target on Pernix Therapeutics (NASDAQ: PTX) to $14.00 (from $17.00) following weak Q2, but maintianed a Buy rating.
Yang commented, "Q2 was a weak quarter for revenue and EPS. Management lowered guidance for a second... More
